SUBSCRIBE: eNewsletter
Learn how two large, phase III studies—HAWK and HARRIER—are the first that “individualize” treatment, says Pravin U. Dugel, MD.
The choice of which anti-vascular endothelial growth factor (VEGF) agent to use on patients with diabetic macular edema (DME) may depend on a variety of variables, including b
Patrik De Haes, MD, CEO of Oxurion NV, shares the latest updates in clinical studies at the [email protected] meeting in Chicago, Oct. 2018.
When used one week after injection, optical coherence tomography angiography can help clinicians determine how effective their treatment has been on neovascular membrane reperfusion.
Using a specific anti-vascular endothelial growth factor (VEGF) drug in patients with moderately severe to severe nonproliferative diabetic retinopathy (NPDR) can result i
Diabetic eye disease is occurring in younger populations, which means it's time to rethink anti-VEGF standards.
With the first ocular gene therapy approved in the United States, Szilard Kiss, MD, points out that the gene therapy era for retinal disease has arrived, “and hopefully it will arrive for age-related macular degeneration.”
We've noticed that you're using an ad blocker
Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.
